Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
- PMID: 37325092
- PMCID: PMC10263095
- DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study
Abstract
Background: There is underutilization of long-acting injectable (LAI) antipsychotics for first-episode schizophrenia (FES) despite having convenient dosing and treatment retention. LAIs are predominantly used for patients with poor compliance, chronic course, and multiple relapses.
Materials and methods: Seventy-two treatment naïve patients with the first episode of Schizophrenia (DSM-5) were assessed for baseline severity of psychopathology using the positive and negative syndrome scale (PANSS) and quality of life (QOL) using the WHOQOL-BREF scale. Patients were randomized to receive either oral haloperidol or LAI haloperidol for a period of 12 weeks.
Results: Both the groups had a significant reduction in PANSS scores and improvement in QoL over 12 weeks period (P = 0.0001). The LAI group showed greater adherence and significantly better quality of life than the oral group (P = 0.023). The mean numbers of side effects were less in the LAI group at week 2 as compared to the oral group.
Conclusion: LAI haloperidol is similar to oral haloperidol in patients with FES with respect to treatment response and offers benefits in form of a lesser number of side effects during early treatment, overall better adherence rates, and better QOL.
Keywords: Adherence; FES; LAI; antipsychotic; first-episode schizophrenia; quality of life.
Copyright: © 2023 Indian Journal of Psychiatry.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x. Pharmacoeconomics. 2016. PMID: 26883132 Free PMC article.
-
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.CNS Drugs. 2021 Nov;35(11):1189-1205. doi: 10.1007/s40263-021-00861-6. Epub 2021 Oct 11. CNS Drugs. 2021. PMID: 34636025 Free PMC article. Review.
-
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315. Turk Psikiyatri Derg. 2022. PMID: 35730516 English, Turkish.
-
Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis.Front Psychiatry. 2020 Jan 8;10:935. doi: 10.3389/fpsyt.2019.00935. eCollection 2019. Front Psychiatry. 2020. PMID: 31969843 Free PMC article.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
Cited by
-
Poorly Recognized and Uncommonly Acknowledged Limitations of Randomized Controlled Trials.Indian J Psychol Med. 2025 Jan;47(1):83-85. doi: 10.1177/02537176241297953. Epub 2024 Nov 20. Indian J Psychol Med. 2025. PMID: 39583300 Free PMC article.
-
Early Intervention in Psychosis and Management of First Episode Psychosis in Low- and Lower-Middle-Income Countries: A Systematic Review.Schizophr Bull. 2024 Apr 30;50(3):521-532. doi: 10.1093/schbul/sbae025. Schizophr Bull. 2024. PMID: 38525604 Free PMC article.
-
Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study.Healthcare (Basel). 2025 Jul 16;13(14):1709. doi: 10.3390/healthcare13141709. Healthcare (Basel). 2025. PMID: 40724735 Free PMC article.
References
-
- Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts”. Clinical features and conceptualization. Schizophr Res. 2009;110:1–23. - PubMed
-
- De Bont R. Schizophrenia, evolution and the borders of biology: On Huxley et al.'s 1964 paper in Nature. Hist Psychiatry. 2010;21:144–59. - PubMed
-
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet. 2008;371:1085–97. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous